# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $8 to $8.25.
Chemotherapy Delivered Via TAMP With Prior Chemoradiation Shows 27-Month Overall Survival; Ongoing Phase III Trial Evaluates Ta...
Ascendiant Capital analyst Edward Woo initiates coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and announces Price Tar...